Madrigal Historical Income Statement
| MDGL Stock | USD 312.00 1.13 0.36% |
Historical analysis of Madrigal Pharmaceuticals income statement accounts such as Total Operating Expenses of 399.5 M can show how well Madrigal Pharmaceuticals performed in making a profits. Evaluating Madrigal Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Madrigal Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Madrigal Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Madrigal Pharmaceuticals is a good buy for the upcoming year.
Madrigal |
About Madrigal Income Statement Analysis
Madrigal Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Madrigal Pharmaceuticals shareholders. The income statement also shows Madrigal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Madrigal Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Madrigal Pharmaceuticals. It is also known as Madrigal Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Madrigal Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Total Other Income Expense Net is quite stable compared to the past year. Selling General Administrative is expected to rise to about 113.6 M this year, although the value of EBIT is projected to rise to (361.5 M).
Madrigal Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Madrigal Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Madrigal Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 11.0M | 4.3M | 1.0M | 4.0M | 12.7M | 13.3M | |
| Other Operating Expenses | 95.0M | 206.7M | 242.5M | 293.6M | 380.5M | 399.5M | |
| Operating Income | (95.0M) | (206.7M) | (242.5M) | (293.6M) | (380.5M) | (361.5M) | |
| Ebit | (95.0M) | (206.7M) | (242.5M) | (293.6M) | (380.5M) | (361.5M) | |
| Research Development | 72.3M | 184.8M | 205.2M | 245.4M | 272.4M | 286.0M | |
| Ebitda | (94.9M) | (206.2M) | (242.1M) | (293.1M) | (380.0M) | (361.0M) | |
| Total Operating Expenses | 95.0M | 206.7M | 242.5M | 293.6M | 380.5M | 399.5M | |
| Net Income | (72.8M) | (197.4M) | (241.1M) | (299.3M) | (373.6M) | (354.9M) | |
| Income Tax Expense | (11.1M) | (4.8M) | (768K) | 4.0M | 4.6M | 4.8M | |
| Depreciation And Amortization | 112K | 471K | 405K | 467K | 527K | 500.7K | |
| Income Before Tax | (83.9M) | (202.2M) | (241.8M) | (295.4M) | (373.6M) | (354.9M) | |
| Total Other Income Expense Net | 11.0M | 4.4M | 636K | (1.8M) | 6.9M | 7.2M | |
| Gross Profit | (112K) | 21.9K | 273K | (467K) | (527K) | (500.7K) | |
| Selling General Administrative | 22.6M | 21.9M | 37.3M | 48.1M | 108.1M | 113.6M | |
| Net Income From Continuing Ops | (83.9M) | (202.3M) | (242.1M) | (295.4M) | (373.6M) | (354.9M) | |
| Cost Of Revenue | 112K | 471K | 405K | 467K | 527K | 553.4K | |
| Net Income Applicable To Common Shares | (83.9M) | (202.2M) | (241.8M) | (295.4M) | (265.8M) | (252.5M) | |
| Interest Income | 11.0M | 4.3M | 363K | 2.2M | 19.6M | 20.6M | |
| Net Interest Income | 11.0M | 4.3M | 363K | (1.8M) | 6.9M | 3.8M | |
| Non Operating Income Net Other | 11.0M | 4.3M | 363K | 2.2M | 2.5M | 4.1M | |
| Reconciled Depreciation | 112K | 471K | 405K | 467K | 527K | 338.6K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.